Last updated 3 months ago

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

412 patients around the world
Available in Panama, Argentina, United States
GlaxoSmithKline
412Patients around the world
This study is for people with
Asthma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy